The RSL3 or Erastin treatment of CRC cell lines did not change the nuclear translocation of Nrf2 in CRC cell lines but significantly reduced antioxidant proteins, which suggest that the RSL3 or Erastin treatment did not impact the activation of Nrf2 signaling but induced ferroptosis by suppression antioxidant proteins. The gene discussed is NFE2L2; the disease is colorectal carcinoma.